SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI, the first approved treatment for Sanfilippo syndrome Type A, is driving attention, along with the associated Priority Review Voucher and anticipated commercial launch. Traders are broadly bullish on the approval and potential short covering, though some debate the muted share reaction, treatment-label and safety considerations, cash burn, and whether the news is already priced in.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

Concerns that Kalshi, Polymarket and other prediction markets are diverting wagering activity and pressuring DraftKings margins are driving the stock-specific selloff, with traders also pointing to customer-friendly NFL results and promotional spending. The community is divided: bears see worsening competition and profitability risks, while bulls cite DKeX growth and a Ninth Circuit ruling that could strengthen state oversight of rival prediction markets.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Reported insider buying by Ryan Cohen, along with expectations of additional GameStop buybacks, is driving bullish attention as the stock and related warrants rise. Traders are linking the move to elevated borrow costs, options activity and potential short-squeeze pressure, while skeptics point to low volume and the lack of a confirmed new announcement.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is drawing attention after the contested Salad and Go acquisition failed to proceed, with traders linking the sharp selloff and repeated 52-week lows to disappointment over the lost expansion opportunity. The community is split between bears focused on the companys premium valuation, interest rates, competition and consumer spending, and bulls arguing the decline is an overreaction given continued store growth and strong operating performance.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves 25-basis-point rate hike and signal that another increase may follow have made IWM a focal point because small caps are viewed as especially sensitive to borrowing costs and Treasury yields. Traders remain divided between bearish views that higher-for-longer rates will extend the Russell 2000s weakness and expectations for a relief bounce or short-covering rally after the selloff.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of topline Phase 3 APPROACH results for HLP003, with traders citing ahead-of-schedule enrollment, promising earlier-stage data, and recent leadership and insider-buying activity. Sentiment is broadly bullish, though the community remains divided over potential dilution, profit-taking, and the binary risk that Phase 3 results may not meet elevated expectations.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is drawing attention after a sharp rally that has significantly outperformed Bitcoin and other major cryptocurrencies, with traders highlighting its privacy focus, fixed supply and possible short liquidations as drivers. Bullish enthusiasm and FOMO dominate, while skeptics describe the move as speculative and overbought, warning of a potential retracement.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Attention is centered on Ultragenyxs FDA approval of FAYUVI (formerly UX111/ABO-102), an Abeona-originated gene therapy that entitles ABEO to milestone payments and royalties. Traders are debating the financial impact, with optimism over a new revenue stream tempered by concerns about the therapys small rare-disease market and limited peak sales potential.

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Schrodinger Inc

Schrdinger is drawing attention after announcing the formation of Tectora, contributing two early-stage small-molecule programs in exchange for an ownership stake, milestone payments, and royalties. Traders view the capital-light structure positively, while some are speculating about additional partnerships or a potential buyout; those takeover expectations remain unconfirmed.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps launch of its Specs augmented-reality glasses and Specs Intelligence AI platform, including enterprise integrations, is driving attention. Traders are split between viewing the technology and partnerships as potentially transformative and arguing that the glasses high cost, uncertain demand, management credibility issues, and repeated sell-the-news pattern are limiting the stocks reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Axon Enterprise is trending following a sharp decline triggered by the company's announcement of a $1 billion offering of 0% convertible senior notes due in 2031, which raised concerns among investors regarding potential shareholder dilution. While some traders view the pullback as a buying opportunity given the company's growth, others expressed frustration with the price action, insider selling, and high valuation multiples.

Strength Seen in Axon (AXON): Can Its 6.0% Jump Turn into More Strength?

Axon (AXON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Investors Heavily Search Axon Enterprise, Inc (AXON): Here is What You Need to Know

Axon (AXON) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Axon Enterprise Prices $1 Bln 0% Convertible Notes Offering, Due 2031

(RTTNews) - Axon Enterprise, Inc. (AXON), a public safety technology company, said Wednesday that it has priced an offering of $1.0 billion in aggregate principal amount of 0% convertible senior notes, which are due in 2031. The sale of the notes to the underwriters is expected t...

Axon Announces Pricing of $1.0 Billion Offering of 0% Convertible Senior Notes Due 2031

Axon Announces Pricing of $1.0 Billion Offering of 0% Convertible Senior Notes Due 2031 Axon Announces Pricing of $1.0 Billion Offering of 0% Convertible Senior Notes Due 2031PR NewswireSCOTTSDALE, Ariz., Sept. 16, 2026 SCOTTSDALE, Ariz., Sept. 16, 2026 /PRNewswire/ -- Axon Enterprise, Inc...

Axon Enterprise (AXON) Dips More Than Broader Market: What You Should Know

Axon Enterprise (AXON) reached $442.31 at the closing of the latest trading day, reflecting a -9.77% change compared to its last close.

Why Rule Breakers Dig Stocks With Multiple Futures

Look back at the stocks that have delivered the biggest gains over the past decade -- including Nvidia (NASDAQ:NVDA), Broadcom (NASDAQ:AVGO), and Axon Enterprise (NASDAQ:AXON) -- and a pattern emerges: None of them won by nailing one single business and sticking to it forever...

Why Axon Enterprise Stock Was Tumbling Today

Key PointsAxon is selling $1 billion in convertible debt...

MSI Secures Public Safety Contract in Louisiana: Will it Fuel Revenues?

MSI lands a $139 million Louisiana public safety contract, expanding its integrated video, software and communications platform.

AXON Plans To Raise $1B Through Convertible Notes — Here’s What Investors Need To Know

Equity

Axon plans to offer $1 billion of 0% convertible senior notes due 2031, with proceeds earmarked for capped call costs and general corporate purposes, including growth initiatives and potential acquisitions or investments in other businesses.


Axon Stock Down 35% Over the Past Year  Now It's Raising $1 Billion in Debt

Axon Enterprise shares are trading lower Tuesday after the company announced a proposed offering of $1.0 billion in convertible senior notes.read more...

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Bullish Sentiment

$APP

$AXON

$BROS

$CELH

$APP, $AXON, $BROS, and $CELH all sold off sharply following Q2 earnings. Which of these earnings declines are you most interested in buying? Vote and explain your reasoning in the comments.

Which of these earnings declines are you most interested in buying - $APP, $AXON, $BROS, or $CELH?

Current Price	$453.50
Prev Close	$468.42
Open	$468.73
Dividend Yield	0.00%
50-Day Moving Average	$554.12
Beta	1.25
Avg. Volume	920,344.01
PE Ratio	193.99

52-Week High	$792.16
52-Week Low	$339.01
Market Capitalization	$38.05B
EPS (Annual)	$1.51
Price to Book	10.36
Revenue Per Employee	$441,196.19

Feed

News

Sentiment

Earnings

Fundamentals

Info

AXON Fundamentals